i) References
  1. World Health Organisation. Onchocerciasis (river blindness) - Disease Information https://www.who.int/blindness/partnerships/onchocerciasis_disease_information/en/ consulted on 14 April 2020.
  2. Kuesel AC. Research for new drugs for elimination of onchocerciasis in Africa. Int J Parasitol Drugs Drug Resist. 2016 May 19. pii: S2211-3207(16)30015-X. doi:10.1016/j.ijpddr.2016.04.002
  3. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010 Oct 2;376(9747):1175-85. doi:10.1016/S0140-6736(10)60586-7. Epub 2010 Aug 23.
  4. Bah GS, Tanya VN, Makepeace BL. Immunotherapy with mutated onchocystatin fails to enhance the efficacy of a sub-lethal oxytetracycline regimen against Onchocerca ochengi. Vet Parasitol. 2015 Aug 15;212(1-2):25-34. doi:10.1016/j.vetpar.2015.06.005. Epub 2015 Jun 12.
  5. Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207-1216.
  6. Pleiss U, Harder A, Turberg A, Londershausen M, Iinuma K, Mencke N, Jeschke P, Bonse G. Synthesis of a radiolabeled cyclodepsipeptide [3H-methyl] PF1022A. J Labelled Comp Radiopharm. 1996;38:61-9.
  7. Omura S, Crump A. The life and times of ivermectin—a success story. Nat Rev Microbiol 2004;2:984–989.
  8. Cotreau MM, et al. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 2003;43:1108–1115
  9. von Samson-Himmelstjerna G, Harder A, Sangster NC, Coles GC. Efficacy of two cyclooctadepsipeptides, PF1022A and emodepside, against anthelmintic-resistant nematodes in sheep and cattle. Parasitol. 2005;130:343-7.
  10. Geary TG, Woo K, McCarthy JS, Mackenzie CD, Horton J, Prichard RK, de Silva NR, Olliaro PL, Lazdins-Helds JK, Engels DA, Bundy DA. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol. 2010 Jan;40(1):1-13. doi: 10.1016/j.ijpara.2009.11.001.
  11. Zahner H et al. Filaricidal efficacy of anthelmintically active cyclodepsipeptides. International Journal for Parasitology. 2001;31:1515-1522.
  12. Zahner H et al. Effects of Bay 44-4400, a new cyclodepsipeptide, on developing stages of filariae (Acanthocheilonema viteae, Brugia malayi, Litomosoides sigmodontis ) in the rodent Mastomys coucha. Acta Tropica 2001 Sep 1;80(1).
  13. Drugs for Neglected Diseasesinitiative . Investigator Brochure Emopdepside - BAY 44-4400. Version 3 dated 8 September 2017.
  14. Committee for Medicinal Products for Human Use (CHMP). Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07 Rev. 1. 20 July 2017.
Data available on request from the authors.